Notably, there were many cancer types, including gliomas, cervical, and kidney carcinomas, with not the highest frequency of overall PARK2 deletion (<40%) but with widespread (up to 69%) decrease or loss of its mRNA expression compared to their normal counterparts (Figures 1B and S1A; >1-log2-fold [red] or >0.5-log2-fold [red and yellow]). The gene discussed is PRKN; the disease is cancer.